Navigation Links
Karyopharm Therapeutics Initiates Two Phase 1 Trials with Oral KPT-330, the First Selective Inhibitor of Nuclear Export (SINE), in Patients with Advanced Cancers
Date:7/25/2012

A funding and the initiation of our Company's operations in late 2010.  This is the first oral SINE to ever enter human studies, and we are eager to assess the potential of our drug candidate across a wide variety of cancers."

The study is being conducted in the United States, Toronto, Canada, and Copenhagen, Denmark. NPM Pharma (Canada) is overseeing the trial on behalf of Karyopharm.

About Karyopharm

Karyopharm is a biopharmaceutical company leading the development of small molecule modulators of nuclear transport.  The Company was founded by Drs. Sharon Shacham and Michael Kauffman in 2008.  Karyopharm has raised approximately $34M since its inception and has won several grants/awards including a Biotech Investment Award by the Multiple Myeloma Research Foundation in 2010. Karyopharm's first program is directed towards the Selective Inhibition of Nuclear Export – its SINE program – targeting CRM1, the major nuclear export protein. SINE compounds, including KPT-330 and KPT-335, force the activation of the cell's key tumor suppressor proteins and anti-inflammatory pathways including p53, p21, pRB, FoxO, and IkB, a key cellular inhibitor of nuclear factor NF-kB. Karyopharm is currently evaluating two oral SINE compounds in clinical trials. KPT-330 oral is being evaluated in patients with cancer, and KPT-335 oral is being studied in dogs with relapsed/refractory non-Hodgkin's Lymphomas.  The Company is also evaluating the use of SINEs in autoimmune/inflammatory disorders, viral infections and dermatologic diseases. Karyopharm Therapeutics is located in Natick, Massachusetts.

contact: Michael Kauffman, 508-975-4821, mkauffman@karyopharm.com   

 


'/>"/>
SOURCE Karyopharm Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Actinium Pharmaceuticals Inc. Pays Regulatory Milestone to Abbott Biotherapeutics Corp.
2. PTC Therapeutics Closes $30 Million Financing
3. Protein and Peptide-based Therapeutics - Trends in Drug Discovery and Development
4. Amsterdam Molecular Therapeutics (AMT) Holding N.V. (in liquidation) Announces Publication of its Accounts for 2011 and Notice of Annual General Meeting
5. Echo Therapeutics Expands License Agreement with Ferndale Pharma
6. PTC Therapeutics Announces Achievement of Major Milestone in Wellcome Trust BMI1 Collaboration
7. Orexigen Therapeutics Announces the Light Study is Enrolling Faster than Originally Projected
8. NIPTE Will Participate in NIHs Therapeutics for Rare and Neglected Diseases (TRND) Program
9. Orexigen Therapeutics to Present at the JMP Securities Healthcare Conference
10. Frost & Sullivan: European Bipolar Therapeutics Market Slows Down in the Short Term As Key Blockbuster Drugs Go Off Patent
11. Oncos Therapeutics Announces Clinical Advisory Board for its Oncolytic Virus and Cancer Immunotherapy Development Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... 2, 2014 Perrigo Company plc, a public limited ... (the " Company "), today announced that it is ... its new 1.30% Senior Notes due 2016 (the " 2016 ... due 2018 (the " 2018 Exchange Notes "), $800,000,000 of ... Exchange Notes ") and $400,00,000 of its new 5.30% Senior ...
(Date:9/2/2014)... 2, 2014  XBiotech announced today interim results ... in the US for its anti-cancer agent Xilonix™. ... therapy, is being evaluated in advanced colorectal cancer ... The primary endpoint of the study is overall ... a control population provided only palliative therapy for ...
(Date:9/2/2014)... Sept. 2, 2014 Reportlinker.com announces that ... its catalogue: Acute Heart Failure Global ... http://www.reportlinker.com/p0689743/Acute-Heart-Failure-Global-Clinical-Trials-Review-H2-2014.html Acute Heart Failure ... Summary GlobalData,s clinical trial report, "Acute Heart ... data on the Acute Heart Failure clinical trial ...
Breaking Medicine Technology:Perrigo Company plc Announces Exchange Offer For Its 1.30% Senior Notes Due 2016, 2.30% Senior Notes Due 2018, 4.00% Senior Notes Due 2023 and 5.30% Senior Notes Due 2043 2Perrigo Company plc Announces Exchange Offer For Its 1.30% Senior Notes Due 2016, 2.30% Senior Notes Due 2018, 4.00% Senior Notes Due 2023 and 5.30% Senior Notes Due 2043 3Perrigo Company plc Announces Exchange Offer For Its 1.30% Senior Notes Due 2016, 2.30% Senior Notes Due 2018, 4.00% Senior Notes Due 2023 and 5.30% Senior Notes Due 2043 4XBiotech Halts Study, Reports Positive Phase III Results with Antibody Therapy for Cancer 2Acute Heart Failure Global Clinical Trials Review, H2, 2014 2Acute Heart Failure Global Clinical Trials Review, H2, 2014 3Acute Heart Failure Global Clinical Trials Review, H2, 2014 4Acute Heart Failure Global Clinical Trials Review, H2, 2014 5Acute Heart Failure Global Clinical Trials Review, H2, 2014 6Acute Heart Failure Global Clinical Trials Review, H2, 2014 7Acute Heart Failure Global Clinical Trials Review, H2, 2014 8
... March 7, 2011 Ajinomoto Co., a leader ... safe, effective nutraceutical solutions, has announced that its ... federal trademark registration, (®), on the Principal Register ...  The trademark is the latest milestone for Capsiate ...
... 7, 2011 HGI Global Holdings, Inc., a leading ... today announced the appointment of Michael B. Petras, Jr. ... Mr. Petras, 43, joins HGI from GE Lighting, ... (NYSE: GE ) where he served as ...
Cached Medicine Technology:Ajinomoto Co.'s Capsiate Natura® Reaches New Milestone 2Michael Petras, Former CEO of GE Lighting, Named CEO of Cleveland-Based Specialty Medical Supplies Leader 2Michael Petras, Former CEO of GE Lighting, Named CEO of Cleveland-Based Specialty Medical Supplies Leader 3
(Date:9/2/2014)... September 02, 2014 The Wm. Jennings Bryan ... and public town hall meeting for Veterans and their families ... the outreach fair to provide Veterans with valuable healthcare and ... town hall will provide a forum where we can gather ... , The outreach fair will be held 4:45 p.m. to ...
(Date:9/2/2014)... Essen, Germany, September 2, 2014 In a ... Germany, researchers found that mild cognitive impairment (MCI) ... diabetes mellitus type 2. Interestingly, this strong association ... whereas in older participants (66-80 years) the association ... Journal of Alzheimer,s Disease . , The concept ...
(Date:9/2/2014)... Operators in the Community Services ... annually, arranging care and counsel for those in need. ... expected to derive $39.4 billion in revenue, which includes ... Over the five years through 2014-15, the subdivision is ... including growth of 4.1% in 2014-15. , As the ...
(Date:9/2/2014)... Steven Reinberg HealthDay Reporter ... device intended to help with weight loss by blocking a ... expectations in a trial among obese patients. Using electric ... brain and stomach, researchers hoped to suppress feelings of hunger. ... "A device that safely blocks the nerve that connects ...
(Date:9/2/2014)... locations with less intensive (and expensive) practice patterns appear ... spare patients unnecessary and excessive medical care, according to ... , "Growing concern about the costs and harms of ... to avoid the provision of unnecessary care," said lead ... The Dartmouth Institute for Health Policy & Clinical ...
Breaking Medicine News(10 mins):Health News:Diabetes mellitus and mild cognitive impairment: Higher risk in middle age? 2Health News:Community Services in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Community Services in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Nerve Blocking Procedure Fails to Impress in Weight Loss Study 2Health News:Nerve Blocking Procedure Fails to Impress in Weight Loss Study 3Health News:Residency training predicts physicians' ability to practice conservatively 2
... within the Academy of Finland,s Research Programme on Substance Use ... aid in smoking reduction therapy. The new drug slows down ... down their smoking. Nicotine is absorbed rapidly through the ... from where it quickly passes through the body and into ...
... Gardner HealthDay Reporter , WEDNESDAY, March 16 (HealthDay ... in a large hospital, more patients died, a new study ... of nursing shortages and cost-cutting, in that the focus should ... the research, appearing in the March 17 issue of the ...
... By Steven Reinberg HealthDay Reporter , ... in the United States reached an all-time low in ... percent from 2008, federal health officials report. , "There ... a statistician at the U.S. Centers for Disease Control ...
... (March 16, 2011) -- On March 28, leading experts ... Congress on Interventional Therapies for Type 2 Diabetes to ... treatment option. The three-day meeting, hosted by NewYork-Presbyterian Hospital/Weill ... together physicians, scientists and policymakers representing 60 countries. The ...
... trial using an all-natural lozenge to treat dry mouth, a ... way at Georgia Health Sciences University College of Dental Medicine. ... closed the faucet, and we want to turn that faucet ... and co-investigator of the study. "The cells and glands that ...
... Young adults are more likely to be heavy drinkers if they ... also had to cope with stressful life events, a new study ... women and 140 men in Germany who were asked about when ... the previous three years, what daily hassles they might have had ...
Cached Medicine News:Health News:New targeted drug helps smokers stub it out 2Health News:When Nurse Staffing Drops, Mortality Rates Rise: Study 2Health News:U.S. Death Rate at All-Time Low: CDC 2Health News:U.S. Death Rate at All-Time Low: CDC 3Health News:Diabetes Surgery 2nd World Congress 2Health News:Diabetes Surgery 2nd World Congress 3Health News:Diabetes Surgery 2nd World Congress 4Health News:Diabetes Surgery 2nd World Congress 5Health News:Clinical trial for dry mouth funded by international oral care award 2Health News:Drinking Behavior May Be Tied to Early Alcohol Use 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: